Zymeworks Return on Investment 2016-2022 | ZYME

Current and historical return on investment (ROI) values for Zymeworks (ZYME) over the last 10 years.
Zymeworks ROI - Return on Investment Historical Data
Date TTM Net Income LT Investments & Debt Return on Investment
2022-03-31 $-0.24B inf%
2021-12-31 $-0.22B inf%
2021-09-30 $-0.21B inf%
2021-06-30 $-0.23B inf%
2021-03-31 $-0.20B inf%
2020-12-31 $-0.19B inf%
2020-09-30 $-0.22B inf%
2020-06-30 $-0.18B inf%
2020-03-31 $-0.17B inf%
2019-12-31 $-0.15B inf%
2019-09-30 $-0.07B inf%
2019-06-30 $-0.06B inf%
2019-03-31 $-0.03B inf%
2018-12-31 $-0.03B inf%
2018-09-30 $-0.01B inf%
2018-06-30 $-0.01B inf%
2018-03-31 $-0.01B inf%
2017-12-31 $-0.01B -66.67%
2017-09-30 $-0.05B -168.25%
2017-06-30 $-0.05B -149.21%
2017-03-31 $-0.05B $0.05B -142.86%
2016-12-31 $-0.04B $0.07B -216.67%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.320B $0.027B
Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00